Promising combo aims to shrink bladder tumors before surgery
NCT ID NCT07639983
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two drugs (trastuzumab rezetecan and camrelizumab) before surgery can improve outcomes for people with a certain type of muscle-invasive bladder cancer (HER2-positive). About 44 adults will receive the treatment to see if it helps eliminate cancer cells or shrink tumors enough to avoid bladder removal. The goal is to find a more effective and tolerable option than standard chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE MUSCLE-INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood draw could spot bladder Cancer's return
- Bladder preservation: a viable alternative to radical surgery?
- Could an ALS drug clear the fog of chemo brain?
- New drug duo aims to wipe out bladder tumors before surgery
- New bladder cancer combo shows promise in Pre-Surgery trial
- Which scan is better for bladder cancer staging? new study aims to find out